Concord Biotech Share Price Today | Stock Price & Concord Biotech Share Screener

Track the current stock price of Concord Biotech with an interactive chart. Analyse CONCORDBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Concord Biotech stock quote in one place.

The quote of ₹1,355.90 sits between the 52-week low of ₹1,014.80 and the 52-week high of ₹1,587.50, and the latest session moved -1.32% from the previous close.

Screen Concord Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CONCORDBIO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, with SUDHIR JAIRAM VAID listed as chairperson or CEO, and it trades under ISIN INE338H01029.

Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies...more

Classification

Identifiers and Leadership

Screen CONCORDBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,235, up from ₹2,034 in 2025.

Latest statistics put total assets at ₹2,235 and shareholder funds at ₹2,015.

Screen Concord Biotech income statement and profit fundamentals. Analyze CONCORDBIO quarterly results. Concord Biotech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Jun, revenue was ₹272 and net profit was ₹58, equal to earnings per unit of ₹5.52, at an operating margin of 32%.

In that period expenses were ₹175, interest cost ₹0 and tax ₹21. The next period listed, 2026-Mar, shows revenue of ₹341 and net profit of ₹89.

Screen CONCORDBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹267, and net cash flow was an inflow of ₹11.

Over the same period, investing activities used ₹143 and financing activities used ₹113.

See Concord Biotech shareholding pattern with promoter, FII, and DII holdings. Check Concord Biotech promoter holding and ownership changes for CONCORDBIO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 44.08%, foreign institutions 7.80%, domestic institutions 9.22% and the public 8.09%, spread across 82,249 shareholders.

The shareholder count was 82,249 in 2026-Mar, compared with 83,325 in 2026-Jun.

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Concord Biotech. Concord Biotech dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹7.55 per unit for 2026-March, a yield of 0.54%, compared with ₹10.70 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹7.55, ₹10.70 and ₹8.75 per unit.

See which indices include Concord Biotech stock. Check CONCORDBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 14 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Get Concord Biotech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Concord Biotech stock events that may affect CONCORDBIO share price, along with derivatives, futures and options activity and sector gainers.

14 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated July 31, 2026, with a record date of July 31, 2026.

It is followed by Annual General Meeting dated July 31, 2026 and Dividend dated July 24, 2026.

Screen CONCORDBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Screen CONCORDBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 5, 2026.

The next most recent announcements are dated October 2, 2026 and October 1, 2026.

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 7 balance sheet periods, 15 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.